Navigation Links
Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry

NEW YORK, June 2 /PRNewswire/ -- Cynvec LLC, a privately held biotechnology company focused on developing novel cancer therapies that harness the apoptotic ability of the sindbis viral vector, today announced that Frank Stonebanks, President and Chief Executive Officer, will make a presentation titled "Cynvec: Breakthrough Oncolytic Viral Vector Therapy with Sindbis" at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry. Mr. Stonebanks' presentation will take place on Wednesday, June 3, 2009 at 10:00 a.m. local time, in Shanghai China. Additional information about the conference can be found at:

About Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed laminin receptor on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing its lead product, CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in the third quarter of 2009. The sindbis vector has demonstrated in vivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found at

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cynvec to Present at New York Biotechnology Association 18th Annual Meeting
2. Cynvec to Present at the BIO National Venture Conference
3. Cynvec LLC(SM) to Present at the Cowen and Company 29th Annual Health Care Conference
4. Cynvec LLC(SM) to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
5. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
6. ViroPharma to Present at Two June Healthcare Conferences
7. Cynosure Announces Presentations at Upcoming Investor Conferences
8. BioMarin to Present at the Goldman Sachs Healthcare Conference
9. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
10. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... today that it has closed the sale of its ... Guerbet (GBT- NYSE Euronext) in a transaction valued at ... manufacturing facilities and a total of approximately 1,000 employees ... St. Louis area. This entire ...
(Date:11/26/2015)... England , November 26, 2015 ... medical device company specializing in imaging technologies, announced today that ... Commission as part of the Horizon 2020 European Union Framework ... out a large-scale clinical trial in breast cancer. ... , --> --> ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
Breaking Biology News(10 mins):